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Use of PlasmaJet for Peritoneal Carcinomatosis
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Patrick Neven, MD, PhD,* Sandrina Lambrechts, MD,* and Ignace Vergote, MD, PhD, FACS, FSPS*
Objective: This study aimed to assess the role and complications of extensive cytoreduction
with PlasmaJet (Plasma Surgical, Roswell, Ga) in ovarian cancerwith peritoneal carcinomatosis.
Materials: All patients undergoing primary, secondary, or interval debulking surgery
for ovarian cancer and treated with PlasmaJet between October 2013 and February 2015
were analyzed.
Results: Nineteen patients were enrolled. The median operative time was 270 minutes,
median blood loss was 700 mL, and median length of stay was 9 days. In all patients,
complete resection of all macroscopic disease was achieved.
We used PlasmaJet to remove peritoneal carcinomatosis on the abdominal peritoneum,
intestinal mesentery, bowel serosa, and diaphragmatic region. Overall, we treated 66 organs
with PlasmaJet in our series. No bowel or urological fistulas were observed. According to
the Clavien-Dindo classification, 13 adverse events were recorded at grade 2 or lesser. We
observed only 1 grade 3 adverse event. No postoperative mortality was recorded.
Conclusions: In our series, the PlasmaJet seems to be an efficient device for tumor ablation
or dissection to obtain complete resection of all macroscopic disease in patients with
peritoneal carcinomatosis.
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Epithelial ovarian cancer (EOC) is the first cause of deathfrom gynecological malignancies. Because of the lack of
specific symptoms in early disease, more than two thirds of
EOC are diagnosed in the advanced stage.
Currently, the standard primary therapy for patients
with advanced EOC is primary debulking surgery aiming to
remove all visible tumor tissue followed by adjuvant che-
motherapy with paclitaxel and carboplatin.
Recently, interval debulking surgery after 3 courses of
neoadjuvant chemotherapy has become a possible treatment
option in patients unable to undergo complete resection during
primary debulking.1Y4 Complete resection of all macroscopic
disease at primary debulking has been shown to be the single
most important independent prognostic factor in advanced
ovarian carcinoma both at primary and interval debulking
surgery.2Y5 In some patients, obtaining the goal of no residual
tumor at debulking surgery is difficult because of extensive
disease on the bowel, diaphragm, and peritoneum. In this setting,
PlasmaJet (PlasmaSurgical,Roswell,Ga) canhelp the surgeon to
obtain an optimal debulking. Secondary cytoreductive surgery is
defined as surgery performed after the completion of the primary
treatment and a disease-free period. Until data from ongoing
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trialswill bemature (GOG213 andAGO-OVARDESKTOP3),
the evidence is based on retrospective studies, suggesting a
benefit of secondary surgery in selected patients.6
The PlasmaJet technology uses neutral plasma energy to
desiccate andvaporize soft tissues.Energy fromargonplasma is
rapidly dissipated as light, kinetic energy, and thermal energy.
The thermal energy produced by the argon plasma also has
unusual properties in that there is a rapid loss of energy from the
particles within the plasma, resulting in only superficial tissue
effects and minimal lateral thermal effects.7 Surprisingly, only
limited minimal data exist on the clinical application of the
PlasmaJet for cytoreduction in peritoneal carcinomatosis,7 and
data from secondary debulking or in interval debulking in EOC
are lacking or only reported as a case report.8
MATERIALS AND METHODS
All patients with widespread peritoneal carcinomatosis
treated with the PlasmaJet scalpel during laparotomy for ovarian
cancer were analyzed. The senior author (I.V.) operated on all
patients with the assistance of the coauthors. PlasmaJet was used
to treat peritoneal deposits of cancer metastases or tumor nodules
on the serosal surface or mesentery of the small and large bowel
as well as tumor deposits on the surface of the liver, diaphragm,
and peritoneum. For diffuse tumor plaques, the PlasmaJet was
used in a painting technique, covering the entire tumor surface
with a continuous sweeping motion in accordance with the
technique described by Bristow9 for Argon-beam coagulator.
In all cases, a median laparotomy was performed. Complete
adhesiolysis, total hysterectomy,bilateral salpingo-oophorectomy,
omentectomy, and resection or a vaporization of all affected or-
gans (small or large bowel, peritoneum, spleen, diaphragm, liver,
etc.) was performed. Paraaortic and pelvic lymphadenectomy
were performed when clinically indicated.
The following characteristics were recorded: age, comor-
bidities, International Federation of Gynecology and Obstetrics
stage, histological type, postoperative residual tumor, presence
of ascites, duration of surgery, previous chemotherapy, organs
operated onwith the PlasmaJet, and previous surgery for ovarian
cancer. Estimated blood loss, length of hospital stay,major/minor
postoperative morbidity, adjuvant therapy, and date of last
follow-up and disease status were also recorded.
Statistical analyses were performed using SPSS 13.0
software (SPSS, Inc, Chicago, Ill). Values are presented as
median and percentage.
RESULTS
From October 2013 to February 2015, we included
19 patients who underwent cytoreductive surgery with
PlasmaJet. The median age was 63 years (39Y85), and
median BMI was 22.8 kg/m2 (18.5Y48.4 kg/m2). At the time
of surgery, 3 (16%) patient underwent primary debulking and
4 (21%) secondary debulking surgery. The remaining 12 patients
(63%) were submitted to interval debulking surgery after
neoadjuvant chemotherapy. Eleven patients (58%) had medical
comorbidities, median operative time was 270 minutes (range,
100Y420 minutes), and median blood loss was 700 mL (range,
100Y2500 mL). Table 1 shows the baseline characteristics.
Four patients did not receive chemotherapy before sur-
gery (3 primary debulking and 1 granulosa cell tumor). Twelve
patients received neoadjuvant chemotherapy (carboplatin-
paclitaxel, 3Y6 cycles). After secondary debulking, all patients
received 6 cycles of carboplatin-paclitaxel. The surgical pro-
cedures performed on all 19 patients are listed in Table 2. Ex-
tensive lymphadenectomy was performed only in patients with
pathologic lymph nodes at imaging before surgery. Seven
patients underwent full lymphadenectomy; the median
number of removed lymph nodes was 41 (range, 22Y59).
Among these patients, 4 have lymph nodal involvement. The
median number of metastatic nodes was 3 (range, 1Y29).
Three patients underwent a partial lymphadenectomy for
bulky nodes. Themedian number of removed lymph nodes in
TABLE 1. Baseline characteristics
Characteristics N (%)
Histology
Serous low grade 4 (21%)
Serous high grade 14 (74%)
Granulosa cell tumor 1 (5%)





Presence of ascites 2 (10%)
FIGO indicates International Federation of Gynecology and
Obstetrics.
TABLE 2. Surgical procedures performed in patients
undergoing cytoreduction with PlasmaJet
Procedure N (%)
TAH/BSO 8 (42%)





Gastric resection 1 (5%)
Omentectomy 14 (73%)
Full-thickness diaphragmatic resection 5 (26%)
Appendectomy 8 (42%)
Colon resection 2 (10%)




Lymph node sampling 4 (21%)
*Enbloc excision of uterus, adnexa, proximal vagina, and rectosigmoid.
TAH/BSO indicates total abdominal hysterectomy/bilateral
salpingo-oophorectomy.
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these patients was 5 (range, 4Y7). All of these patients have
lymph nodal involvement with a median number of meta-
static nodes of 2 (range, 2Y3).
In all patients, a complete resection of all macroscopic
diseasewas achieved. The abdominopelvic cavity was divided
into 4 anatomic regions. The regions are listed in Table 3. For
each region, the use of PlasmaJet was possible. The median
number of organs treated by PlasmaJet was 3 (range, 1Y7).
In total, we treated 66 organs with PlasmaJet in 19 pa-
tients. Figures 1 and 2 show the use of PlasmaJet on the dia-
phragm and the small bowel.
Six patients (32%) had intraoperative complications.
Five patients required blood transfusion, and one of them also
needed the administration of frozen plasma. The only major
intraoperative complication was a ureteral injury, which re-
quired double-j stent (not during use of PlasmaJet). The
median length of hospital stay was 9 days (6Y21 days). Eight
patients (42%) had postoperative complications. One patient
developed pneumonia and was successfully treated with antibi-
otics. Three patients needed blood transfusions postoperatively.
Two patients had a urinary tract infection. One patient developed
a wound infection and necrosis requiring a 21-day hospital stay.
In this patient, during surgery, abdominal port-site metastases
were removed. One patient developed a pneumothorax. In this
patient, a full-thickness diaphragmatic resection was performed,
done during surgery.
No bowel or urological fistulas occurred. According to
the Clavien-Dindo classification,10 13 (93%) adverse events
grade 1 or 2 were recorded. We observed only 1 (7%) grade 3
adverse event. No mortality was reported.
Themedian follow-up after cytoreduction was 8months
(range, 0Y17). During this period, 6 patients had a relapse. To
date, 13 (68%) are alive without disease, 4 (21%) are alive
with disease, and 2 patients (10%) died of disease.
DISCUSSION
To the best of our knowledge, this report represents the
largest series on the use of the PlasmaJet in ovarian cancer. In
our series, the PlasmaJet seems to be an efficient device for
tumor ablation or dissection to obtain complete resection of all
macroscopic disease in patientswith peritoneal carcinomatosis.
The PlasmaJet was widely used in this study on every
tumor deposit on several organs. In particular, the PlasmaJet
facilitated the removal of disease on the bowel serosa andmight
reduce the need for bowel resection. In this series, all patients
TABLE 3. Anatomic region treated with the PlasmaJet
Number (%)
Abdominal peritoneum 14 (74%)
Paracolic fossa 6 (32%)
Douglas peritoneum/pararectal space 11 (58%)
Bladder peritoneum 3 (16%)
Abdominal wall 3 (16%)
Intestinal mesentery 11 (58%)
Bowel serosa 11 (58%)
Rectosigmoid 6 (32%)
Small bowel 4 (21%)
Colon 3 (16%)
Stomach 2 (16%)
Upper abdomen 14 (74%)
Diaphragm 13 (68%)
Liver surface 4 (21%)
FIGURE 1. PlasmaJet ablation of carcinomatosis
on the small bowel.
FIGURE 2. PlasmaJet ablation carcinomatosis on
the diaphragm.
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were resected to nomacroscopic residual tumor, and no fistulas
occurred. Further experience and a longer follow-up period are
required to establish the use of the PlasmaJet in cytoreductive
surgery of ovarian cancer.
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